New Type of Syringe

liver411

Article TERUMO begins commercial production of the Auto-Disable Syringe Licensed by Univec, Inc. Contributing to safer injection practices 12/17/2001 FARMINGDALE, N.Y., Dec 17, 2001 (BUSINESS WIRE) -- Univec the Farmingdale-based UNIVEC, Inc. (OTCBB:UNVC), which licensed its technology to Terumo Europe N.V. is happy to share this press release from Terumo Europe N.V. indicating that Terumo Europe N.V. has launched its new Auto-Disable Syringes. With its AD-Syringes, TERUMO contributes to safer injection practices and helps to reduce the risk of cross-contamination and injection-associated transmission of blood-borne pathogens, such as hepatitis B, hepatitis C and HIV infections. The key feature of TERUMO AD-Syringe is the locking mechanism, which locks the plunger once the syringe plunger is depressed. This means that TERUMO AD-Syringe is preventing the re-use of the syringe. With its AD-Syringes, TERUMO is answering to the joint policy statement issued by WHO, UNICEF and UNFPA, which urge all countries to use AD-syringes for administering vaccines. TERUMO AD-Syringes obtained all certifications required, complying with the WHO/V&B Performance Specification E8/ DS1 - 1 October 1999 and the European directive for medical devices MDD 93/42/ECC. TERUMO Europe NV is an affiliate of TERUMO Corporation - Japan, a global medical technology company that develops, manufactures and markets a broad range of products and services. Univec is a world leader in auto-disable syringes and is leading the global movement for a conversion to auto-disable syringes from traditional multi-use syringes. Traditional multi-use disposable syringes are recognized by the World Health Organization to be responsible for the spread of diseases to millions of people each year. Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in the company's Securities and Exchange filings under "Risk Factors," including risks relating to dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the company's proposed products (such as marketing, safety, regulatory, patent product liability, supply, competition and other risks.) CONTACT: Univec, Inc. Joel Schoenfeld [email protected] (631) 777-2000 or Terumo Europe N.V. Florence Pivert [email protected] (33) 618606779 URL:http://www.businesswire.com Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page.